Journal articleEClinicalMedicine2023

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial.

DOI 10.1016/j.eclinm.2023.101897 ↗ OpenAlex, retrieved 5 November 2026

Journal: EClinicalMedicine
Published: 16 March 2023
Citations: 27
Type: Article
License: cc by-nc-nd

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Trials 1

Its registry lists this paper as resultsA Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma NCT02993731 ↗

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.